2-(5-Nitrofuran-2-yl)ethan-1-ol | 1340270-51-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: 2-(5-Nitrofuran-2-yl)ethan-1-ol
• 英文别名: 2-(5-nitrofuran-2-yl)ethanol
• CAS: 1340270-51-0
• 化学式: C₆H₇NO₄
• 分子量: 157.126
• InChiKey: HNYOZTKYBQNRLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  79.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-氯-4-羟基苯甲醛 、 2-(5-Nitrofuran-2-yl)ethan-1-ol 在 哌啶 、 溶剂黄146 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 生成 5-(3-chloro-4-(2-(5-nitrofuran-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
  参考文献：
  名称：

  Control of the intracellular levels of prostaglandin E2 through inhibition of the 15-hydroxyprostaglandin dehydrogenase for wound healing

  摘要：

  Excessive scar formation is an aberrant form of wound healing and is an indication of an exaggerated function of fibroblasts and excess accumulation of extracellular matrix during wound healing. Much experimental data suggests that prostaglandin E-2 (PGE(2)) plays a role in the prevention of excessive scarring. However, it has a very short half-live in blood, its oxidization to 15-ketoprostaglandins is catalyzed by 15-hydroxyprostaglandin dehydrogenase (15-PGDH). Previously, we reported that 15-PGDH inhibitors significantly increased PGE(2) levels in A549 cells. In our continuing attempts to develop highly potent 15-PGDH inhibitors, we newly synthesized various thiazolidine-2,4-dione derivatives. Compound 27, 28, 29, and 30 demonstrated IC50 values of 0.048, 0.020, 0.038 and 0.048 mu M, respectively. They also increased levels of PGE(2) in A549 cells. Especially, compound 28 significantly increased level of PGE(2) at 260 pg/mL, which was approximately fivefold higher than that of control. Scratch wounds were analyzed in confluent monolayers of HaCaT cells. Cells exposed to compound 28 showed significantly improved wound healing with respect to control. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.05.049

文献信息

• Oxazolidinone derivatives as pontential antimicrobials
  申请人：——

  公开号：US20040242591A1

  公开（公告）日：2004-12-02

  The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacteroides spp. and Clostridium spp. species, and acid fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp.

  本发明涉及某些取代苯基噁唑啉酮以及其合成的方法。本发明还涉及含有本发明化合物作为抗微生物药物的制剂。这些化合物是有用的抗微生物剂，对许多人类和兽医病原体有效，包括革兰氏阳性的需氧菌，如多重耐药葡萄球菌、链球菌和肠球菌，以及厌氧菌，如Bacteroides属和Clostridium属物种，以及酸性快速菌，如结核分枝杆菌、埃及分枝杆菌和分枝杆菌属。
• OXAZOLIDINONE DERIVATIVES AS POTENTIAL ANTIMICROBIALS
  申请人：RANBAXY LABORATORIES, LTD.

  公开号：EP1409464A1

  公开（公告）日：2004-04-21
• [EN] OXAZOLIDINONE DERIVATIVES AS POTENTIAL ANTIMICROBIALS<br/>[FR] DERIVES D'OXAZOLIDINONE UTILISES COMME ANTIMICROBIENS POTENTIELS
  申请人：RANBAXY LAB LTD

  公开号：WO2003008389A1

  公开（公告）日：2003-01-30

  The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacteroides spp. and Clostridium spp. species, and acid fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp.
• Control of the intracellular levels of prostaglandin E2 through inhibition of the 15-hydroxyprostaglandin dehydrogenase for wound healing
  作者：Dubok Choi、Yu Lan Piao、Ying Wu、Hoon Cho

  DOI：10.1016/j.bmc.2013.05.049

  日期：2013.8

  Excessive scar formation is an aberrant form of wound healing and is an indication of an exaggerated function of fibroblasts and excess accumulation of extracellular matrix during wound healing. Much experimental data suggests that prostaglandin E-2 (PGE(2)) plays a role in the prevention of excessive scarring. However, it has a very short half-live in blood, its oxidization to 15-ketoprostaglandins is catalyzed by 15-hydroxyprostaglandin dehydrogenase (15-PGDH). Previously, we reported that 15-PGDH inhibitors significantly increased PGE(2) levels in A549 cells. In our continuing attempts to develop highly potent 15-PGDH inhibitors, we newly synthesized various thiazolidine-2,4-dione derivatives. Compound 27, 28, 29, and 30 demonstrated IC50 values of 0.048, 0.020, 0.038 and 0.048 mu M, respectively. They also increased levels of PGE(2) in A549 cells. Especially, compound 28 significantly increased level of PGE(2) at 260 pg/mL, which was approximately fivefold higher than that of control. Scratch wounds were analyzed in confluent monolayers of HaCaT cells. Cells exposed to compound 28 showed significantly improved wound healing with respect to control. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.